Given the intense public debate over access to and pricing of patented medicines, academics, policymakers, lawyers, and others have begun to think creatively about what it is that actually incentivises innovation and encourages drug development. While doing so, it is important to identify the points in the R&D process where the failures occur. There are … Continue reading Guest column : Are “prizes” to reward drug R&D a viable alternative to patents?
Apothecurry 